de State Street Catalyst Pharmaceutical CPRX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 240 M | Comprar |
7,627,036
+763,976
| +11% | +USD 22.5 M | 0.01% | 941 |
|
|
2026
Q1 | USD 170 M | Vender |
6,863,060
-44,562
| -0.6% | -USD 1.06 M | 0.01% | 1035 |
|
|
2025
Q4 | USD 161 M | Comprar |
6,907,622
+502,235
| +8% | +USD 11.2 M | 0.01% | 1076 |
|
|
2025
Q3 | USD 126 M | Comprar |
6,405,387
+926,999
| +17% | +USD 19.1 M | ﹤0.01% | 1208 |
|
|
2025
Q2 | USD 119 M | Vender |
5,478,388
-52,049
| -0.9% | -USD 1.23 M | ﹤0.01% | 1211 |
|
|
2025
Q1 | USD 134 M | Vender |
5,530,437
-266,123
| -5% | -USD 5.99 M | 0.01% | 1114 |
|
|
2024
Q4 | USD 121 M | Comprar |
5,796,560
+111,230
| +2% | +USD 2.39 M | ﹤0.01% | 1232 |
|
|
2024
Q3 | USD 113 M | Vender |
5,685,330
-347,968
| -6% | -USD 6.45 M | ﹤0.01% | 1261 |
|
|
2024
Q2 | USD 93.5 M | Vender |
6,033,298
-2,119,604
| -26% | -USD 33 M | ﹤0.01% | 1306 |
|
|
2024
Q1 | USD 130 M | Comprar |
8,152,902
+1,365,570
| +20% | +USD 20.6 M | 0.01% | 1147 |
|
|
2023
Q4 | USD 114 M | Vender |
6,787,332
-783,363
| -10% | -USD 10.7 M | 0.01% | 1215 |
|
|
2023
Q3 | USD 88.5 M | Vender |
7,570,695
-1,882,382
| -20% | -USD 25.2 M | ﹤0.01% | 1265 |
|
|
2023
Q2 | USD 127 M | Comprar |
9,453,077
+1,910,359
| +25% | +USD 27.5 M | 0.01% | 1065 |
|
|
2023
Q1 | USD 125 M | Vender |
7,542,718
-330,596
| -4% | -USD 5.45 M | 0.01% | 1042 |
|
|
2022
Q4 | USD 146 M | Comprar |
7,873,314
+317,891
| +4% | +USD 4.89 M | 0.01% | 931 |
|
|
2022
Q3 | USD 96.9 M | Comprar |
7,555,423
+2,117,944
| +39% | +USD 25.1 M | 0.01% | 1116 |
|
|
2022
Q2 | USD 38.1 M | Comprar |
5,437,479
+819,524
| +18% | +USD 6.01 M | ﹤0.01% | 1828 |
|
|
2022
Q1 | USD 38.3 M | Vender |
4,617,955
-433,034
| -9% | -USD 3.06 M | ﹤0.01% | 1925 |
|
|
2021
Q4 | USD 34.2 M | Vender |
5,050,989
-1,018,392
| -17% | -USD 6.7 M | ﹤0.01% | 2084 |
|
|
2021
Q3 | USD 32.2 M | Comprar |
6,069,381
+70,933
| +1% | +USD 388 k | ﹤0.01% | 2135 |
|
|
2021
Q2 | USD 34.5 M | Vender |
5,998,448
-2,935,535
| -33% | -USD 15.1 M | ﹤0.01% | 2123 |
|
|
2021
Q1 | USD 41.2 M | Comprar |
8,933,983
+2,820,053
| +46% | +USD 11.2 M | ﹤0.01% | 1887 |
|
|
2020
Q4 | USD 20.4 M | Vender |
6,113,930
-1,518,422
| -20% | -USD 5.1 M | ﹤0.01% | 2227 |
|
|
2020
Q3 | USD 22.7 M | Comprar |
7,632,352
+955,751
| +14% | +USD 3.74 M | ﹤0.01% | 1967 |
|
|
2020
Q2 | USD 30.8 M | Vender |
6,676,601
-764,221
| -10% | -USD 3.43 M | ﹤0.01% | 1764 |
|
|
2020
Q1 | USD 28.6 M | Comprar |
7,440,822
+22,527
| +0.3% | +USD 92.5 k | ﹤0.01% | 1602 |
|
|
2019
Q4 | USD 27.8 M | Comprar |
7,418,295
+3,791,669
| +105% | +USD 17.7 M | ﹤0.01% | 1905 |
|
|
2019
Q3 | USD 19.3 M | Comprar |
3,626,626
+1,805,435
| +99% | +USD 9.6 M | ﹤0.01% | 2091 |
|
|
2019
Q2 | USD 6.99 M | Comprar |
1,821,191
+194,096
| +12% | +USD 838 k | ﹤0.01% | 2653 |
|
|
2019
Q1 | USD 8.3 M | Comprar |
1,627,095
+71,118
| +5% | +USD 209 k | ﹤0.01% | 2551 |
|
|
2018
Q4 | USD 2.99 M | Comprar |
1,555,977
+28,527
| +2% | +USD 81.7 k | ﹤0.01% | 2953 |
|
|
2018
Q3 | USD 5.77 M | Comprar |
1,527,450
+88,522
| +6% | +USD 277 k | ﹤0.01% | 2792 |
|
|
2018
Q2 | USD 4.49 M | Comprar |
1,438,928
+235,288
| +20% | +USD 714 k | ﹤0.01% | 2916 |
|
|
2018
Q1 | USD 2.88 M | Comprar |
1,203,640
+65,842
| +6% | +USD 219 k | ﹤0.01% | 3031 |
|
|
2017
Q4 | USD 4.45 M | Comprar |
1,137,798
+193,503
| +20% | +USD 639 k | ﹤0.01% | 2841 |
|
|
2017
Q3 | USD 2.38 M | Comprar |
944,295
+6,100
| +0.7% | +USD 16.7 k | ﹤0.01% | 3126 |
|
|
2017
Q2 | USD 2.59 M | Comprar |
938,195
+892,895
| +1,971% | +USD 1.86 M | ﹤0.01% | 3026 |
|
|
2017
Q1 | USD 88 k | Mantener |
45,300
| – | – | ﹤0.01% | 3547 |
|
|
2016
Q4 | USD 47 k | Mantener |
45,300
| – | – | ﹤0.01% | 3565 |
|
|
2016
Q3 | USD 49 k | Mantener |
45,300
| – | – | ﹤0.01% | 3486 |
|
|
2016
Q2 | USD 33 k | Vender |
45,300
-1,148,674
| -96% | -USD 925 k | ﹤0.01% | 3622 |
|
|
2016
Q1 | USD 1.4 M | Comprar |
1,193,974
+61,345
| +5% | +USD 95.2 k | ﹤0.01% | 3122 |
|
|
2015
Q4 | USD 2.78 M | Comprar |
1,132,629
+102,198
| +10% | +USD 293 k | ﹤0.01% | 2861 |
|
|
2015
Q3 | USD 3.1 M | Comprar |
1,030,431
+369,172
| +56% | +USD 1.59 M | ﹤0.01% | 2785 |
|
|
2015
Q2 | USD 2.73 M | Comprar |
661,259
+616,859
| +1,389% | +USD 2.46 M | ﹤0.01% | 2939 |
|
|
2015
Q1 | USD 193 k | Mantener |
44,400
| – | – | ﹤0.01% | 3497 |
|
|
2014
Q4 | USD 133 k | Vender |
44,400
-5,000
| -10% | -USD 13.7 k | ﹤0.01% | 3532 |
|
|
2014
Q3 | USD 164 k | Comprar |
49,400
+2,200
| +5% | +USD 5.75 k | ﹤0.01% | 3494 |
|
|
2014
Q2 | USD 120 k | Mantener |
47,200
| – | – | ﹤0.01% | 3454 |
|
|
2014
Q1 | USD 107 k | Mantener |
47,200
| – | – | ﹤0.01% | 3502 |
|
|
2013
Q4 | USD 92 k | Comprar |
+47,200
| Nuevas | +USD 95.4 k | ﹤0.01% | 3491 |
|
Otros fondos que tienen CPRX en su cartera
Posición de State Street en CPRX: resumen de T2 2026
State Street aumentó su participación en Catalyst Pharmaceutical (CPRX) en 11% durante T2 2026, al comprar aproximadamente USD 22.5 M y elevar la posición a 7,627,036 acciones con un valor de USD 240 M. La posición representa 0.01% de la cartera y ocupa el puesto #941.
State Street reportó por primera vez una posición en CPRX en T4 2013 y la ha mantenido durante 51 trimestres desde entonces. Al cierre de T2 2026, 398 fondos que sigue Wall St. Rank mantienen una posición en CPRX.
- Al cierre de T2 2026, State Street tenía 7,627,036 acciones de Catalyst Pharmaceutical con un valor de USD 240 M.
- State Street compró 763,976 acciones de Catalyst Pharmaceutical en T2 2026, por un monto estimado de USD 22.5 M.
- Catalyst Pharmaceutical representó 0.01% de la cartera de State Street en T2 2026 y fue su posición número 941.
- State Street reportó por primera vez una posición en Catalyst Pharmaceutical en T4 2013 y la ha mantenido durante 51 trimestres desde entonces.
- Al cierre de T2 2026, 398 fondos que sigue Wall St. Rank tenían Catalyst Pharmaceutical en cartera.
Según el Informe 13F de State Street correspondiente a T2 2026, presentado el 7 ago 2026.